levodopa has been researched along with selegiline in 417 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 104 (24.94) | 18.7374 |
| 1990's | 197 (47.24) | 18.2507 |
| 2000's | 82 (19.66) | 29.6817 |
| 2010's | 27 (6.47) | 24.3611 |
| 2020's | 7 (1.68) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Rinne, UK | 6 |
| Lander, CM; Lees, A; Stern, G | 1 |
| Antal, J; Antóny, M; Csanaky, A; Csanda, E | 1 |
| Knoll, J | 4 |
| Yahr, MD | 2 |
| Birkmayer, W | 4 |
| Lees, AJ; Sandler, M; Stern, GM | 1 |
| Rinne, UK; Siirtola, T; Sonninen, V | 1 |
| Lieberman, A | 5 |
| Siemers, E | 1 |
| Olanow, CW | 4 |
| Nag, D | 1 |
| Ahuja, GK; Behari, M; Prasad, K; Singh, K | 1 |
| Clow, A; Dexter, D; Glover, V; Hussain, T; Sandler, M; Walker, M | 1 |
| Dietrichs, E | 1 |
| Levivier, M; Przedborski, S | 1 |
| Kovács, A | 1 |
| Baronti, F; Boldry, RC; Chase, TN; Davis, TL; Mouradian, MM | 1 |
| Casarejos, MJ; Fahn, S; García de Yébenes, J; Mena, MA; Pardo, B | 1 |
| Málly, J | 1 |
| LeWitt, PA | 2 |
| Madeja, UD | 1 |
| Anderson, JJ; Bravi, D; Chase, TN; Dagani, F; Davis, TL; Ferrari, R; Gillespie, M | 1 |
| Männistö, PT; Törnwall, M | 1 |
| Heinonen, EH; Lammintausta, R | 1 |
| Marsden, CD | 1 |
| Kuhn, W; Przuntek, H | 2 |
| Horowski, R; Runge, I | 1 |
| Riggs, JE | 1 |
| Fazzini, E; Lieberman, A | 1 |
| Allain, H; Cougnard, J; Neukirch, HC | 1 |
| Rinne, JO | 1 |
| Elizan, TS; Moros, DA; Yahr, MD | 1 |
| Grimes, JD | 1 |
| Jacobs, MB; Varon, J | 1 |
| Cedarbaum, JM; Green-Parsons, A; Toy, LH | 1 |
| Waters, CH | 2 |
| Asari, S; Goldstein, M; Nakashima, H; Nishimoto, A | 1 |
| Hauser, RA; Olanow, CW | 1 |
| Dluzen, DE; McDermott, JL | 1 |
| Dettner, O; Gerlach, M; Kuhn, W; Przuntek, H; Russ, H | 1 |
| Ahlskog, JE; Wilkinson, JM | 1 |
| George, CF; Robertson, DR | 1 |
| Cedarbaum, JM; Clark, M; Harts, A; Kutt, H; Silvestri, M | 1 |
| Quinn, N | 2 |
| Baas, H; Fischer, PA | 2 |
| Bodian, CA; Elizan, TS; Mendoza, MR; Moros, DA; Pang, S; Yahr, MD | 3 |
| Fornadi, F; Ulm, G | 2 |
| Susel, Z; Yarnitsky, D | 1 |
| Cohen, G | 2 |
| Hodges, LC; Rapp, CG | 1 |
| Kraus, P; Kuhn, W; Przuntek, H | 1 |
| Calne, DB; Calne, S; Douglas, J; Postnikoff, D; Poulin, K; Ross, S; Tsui, JK; Woodward, W | 1 |
| Lewin, R | 2 |
| Langston, JW; Tetrud, JW | 2 |
| Eatough, VM; Frankel, JP; Kempster, PA; Lees, AJ; Nathanson, M; Stern, GM; Stibe, CM | 1 |
| Defazio, G; Ferrari, E; Lamberti, P; Lepore, V; Livrea, P | 1 |
| Heinonen, EH; Rinne, UK | 1 |
| Heinonen, EH; Rinne, UK; Tuominen, J | 1 |
| Parker, S; Teychenne, PF | 1 |
| Aljanati, R; Buzo, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Romero, S; Scaramelli, A | 1 |
| Eatough, V; Frankel, J; Lees, AJ; Stern, GM | 1 |
| Boesen, F; Dupont, E; Heinonen, E; Mikkelsen, B; Mogensen, P; Rasmussen, C; Sivertsen, B | 1 |
| Elizan, TS; Moros, D; Yahr, MD | 1 |
| Goetz, CG; Klawans, HL; Rajput, AH; Tanner, CM; Thiessen, B; Uitti, RJ | 1 |
| Kaakkola, S; Männistö, PT; Nuutila, J | 1 |
| Fozard, JR; Palfreyman, MG; Robin, M; Zreika, M | 1 |
| Agnoli, A; Carta, A; Denaro, A; Meco, G; Ruggieri, S; Stocchi, F | 1 |
| Jenner, P; Marsden, CD | 1 |
| Stern, G | 2 |
| Bretton, C; Hof, P; Ofori, S; Schorderet, M | 1 |
| Cacudi, N; de Mari, M; Ferrari, E; Iliceto, G; Lamberti, P | 1 |
| Caraceni, T; Giovannini, P; Piccolo, I; Scigliano, G | 1 |
| Birkmayer, GD; Birkmayer, W | 1 |
| Agnoli, A; Baronti, F; Denaro, A; Ruggieri, S; Stocchi, F | 1 |
| Caraceni, T; Giovannini, P; Grassi, MP; Martignoni, E; Nappi, G; Pacchetti, C; Piccolo, I | 1 |
| Csanda, E; Takáts, A; Tárczy, M | 1 |
| Youdim, MB | 2 |
| Bizière, K; Kan, JP; Roncucci, R; Wermuth, CG; Worms, P | 1 |
| Finberg, JP; Youdim, MB | 1 |
| Birkmayer, JD; Birkmayer, W | 1 |
| Angers, M; Nguyen, TB | 1 |
| Aminoff, MJ | 1 |
| Berstad, J; Lien, K; Presthus, J | 1 |
| Dubuis, R | 1 |
| Duvoisin, RC; Golbe, LI | 1 |
| Foo, SH; Gopinathan, G; Lieberman, AN; Neophytides, A | 1 |
| Ahlskog, JE; Duvoisin, RC; Foo, SH; Golbe, LI; Gopinathan, G; Lieberman, AN; Muenter, MD; Neophytides, AN | 1 |
| Demonet, JF; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM; Simonetta, M | 1 |
| Calne, DB; Rinne, UK | 1 |
| Caraceni, T; Giovannini, P; Grassi, MP; Piccolo, I; Scigliano, G; Soliveri, P | 1 |
| Adam, AM | 1 |
| Daniele, D; Gillio, S; Scarzella, L; Trebini, F | 1 |
| Wirz, D | 1 |
| Birkmayer, W; Hars, V; Knoll, J; Marton, J; Riederer, P; Youdim, MB | 1 |
| Hietala, J; Koulu, M; Scheinin, M; Syvälahti, E | 1 |
| Weiner, M | 1 |
| Colucci d'Amato, C; Cristillo, A; Puccini, A; Vizioli, R | 1 |
| Calne, DB; Ebert, MH; Eisler, T; Kopin, IJ; Krebs, H; Lake, CR; Murphy, DL; Nelson, R; Teräväinen, H; Weise, V; Whetzel, N | 1 |
| Birkmayer, W; Knoll, J; Riederer, P; Youdim, MB | 1 |
| Gallai, M; Tariska, I | 1 |
| Baraczka, K; Fekete, MI; Kanyicska, B | 1 |
| Birkmayer, W; Riederer, P | 1 |
| Bihari, K; Csanda, E; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M | 1 |
| Rabey, MJ; Streifler, M | 1 |
| Csanda, E; Katona, G; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M | 1 |
| Goodgold, A; Gopinathan, G; Hiesiger, E; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 1 |
| Csanda, E; Tárczy, M | 2 |
| Gerstenbrand, F; Poewe, W; Ransmayr, G | 1 |
| Hajba, A; Presthus, J | 1 |
| Portin, R; Rinne, UK | 1 |
| Koulu, M; Lammintausta, R | 2 |
| Bergmann, KJ; Mendoza, MR; Moros, D; Yahr, MD | 1 |
| Quinn, NP | 1 |
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
| Csanaky, A; Gyimóti, G; Leposa, D | 1 |
| Reiderer, P; Reynolds, GP | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Jenner, P; Marsden, CD; Parkes, JD; Schachter, M; Testa, B | 1 |
| Cabbat, FS; Duvoisin, RC; Heikkila, RE; Manzino, L | 1 |
| Calne, DB; Chuang, LW; Eisler, T; Karoum, F; Klein, DF; Liebowitz, MR; Quitkin, FM; Wyatt, RJ | 1 |
| Elsworth, JD; Lees, AJ; Sandler, M; Stern, GM; Ward, C | 1 |
| Birkmayer, W; Riederer, P; Youdim, MB | 1 |
| Antóny, M; Széplaki, Z; Tóth, G | 1 |
| Ghika, J | 1 |
| Bushenbark, K; Esterlitz, J; Gauger, L; Hauser, RA; Hubble, J; Koller, W; Lilienfeld, D; Malapira, T; Olanow, CW | 1 |
| Eadie, MJ | 1 |
| Ludin, HP | 1 |
| Bankiewicz, KS; Finberg, JP; Goldstein, DS; Kopin, IJ; Wang, J | 1 |
| Fahn, S; Jackson-Lewis, V; Przedborski, S | 1 |
| Burns, RS; Davis, TL; Roznoski, M | 2 |
| Janjua, R; Roos, RA; van Kempen, GM | 1 |
| Sweeney, PJ | 1 |
| Danysz, W; Quack, G; Rogoz, Z; Skuza, G | 1 |
| Carter, J; Fahn, S; Gauthier, S; Goetz, CG; Golbe, LI; Jankovic, J; Koller, W; Lang, AE; McDermott, MP; Olanow, CW | 1 |
| Hastie, IR; Mukherjee, D | 1 |
| Heinonen, EH; Kilkku, OI; Myllylä, VV; Sotaniemi, KA; Vuorinen, JA | 1 |
| Brannan, T; Yahr, MD | 1 |
| Bhatia, M; Jain, S; Maheshwari, MC | 1 |
| Haas, RH; Hill, LR; Nakano, K; Nasirian, F; Pay, M; Shults, CW; Ward, DM | 1 |
| Adams, CE; Boyson, SJ; Hoffer, BJ; Hoffman, AF; Hudson, JL | 1 |
| Bennett, KM; Castiello, U | 1 |
| Beizer, JL | 1 |
| Eberli, F; Greminger, P; Schmid, PA; Speich, R; Suter, T | 1 |
| Yoshida, M | 1 |
| Imai, T; Nakamura, Y; Ogawa, N; Tachibana, H; Takahashi, M; Yorifuji, S; Yuasa, R | 1 |
| Kondo, T; Mizuno, Y; Takubo, H; Yokochi, F | 2 |
| Bennett, JP; Parker, WD; Smith, TS | 1 |
| Standaert, DG; Stern, MB | 1 |
| Finali, G; Piccinin, GL; Piccirilli, M | 1 |
| Calne, DB; Uitti, RJ; Vingerhoets, FJ | 1 |
| Dichgans, J; Klockgether, T | 1 |
| Ahlskog, JE | 3 |
| Abercrombie, ED; Wachtel, SR | 1 |
| Bulgaru, D; Büttner, T; Klotz, P; Kuhn, W; Przuntek, H; Steinberg, R; Voss, L | 1 |
| Allain, H; Neukirch, HC; Pollak, P | 1 |
| Heinonen, EH; Myllylä, VV; Sotaniemi, KA; Vuorinen, JA | 1 |
| Fahn, S; García de Yébenes, J; Mena, MA; Pardo, B | 1 |
| Boulton, AA; Juorio, AV; Li, XM; Paterson, IA | 1 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW | 1 |
| Hubble, JP; Koller, WC; Waters, C | 1 |
| Koivikko, L; Portin, R; Revonsuo, A; Rinne, JO; Rinne, UK | 1 |
| Silverstein, PM | 1 |
| Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ | 1 |
| Macklin, BS; O'Shea, N; Renwick, AG; Roberts, J; Waller, DG | 1 |
| Calne, DB | 2 |
| Lees, AJ | 1 |
| Heinonen, E; Kilkku, O; Mäki-Ikola, O | 1 |
| Anderson, KE; Girdwood, AC; Wilson, JA | 1 |
| Godbold, JH; Koller, W; Olanow, CW | 1 |
| Jenner, P; Silva, MT; Watts, PM | 1 |
| Bland, R; MacMahon, DG | 1 |
| Boulton, AA; Lai, CT; Yu, PH | 1 |
| Gerlach, M; Riederer, P; Vogt, H | 1 |
| Jellinger, KA | 1 |
| Fahn, S | 1 |
| Ahlskog, JE; Low, PA; Nickander, KK; O'Brien, JF; Tyce, GM; Uitti, RJ | 1 |
| Brownlee, HJ; Stacy, M | 1 |
| Newton, W | 1 |
| Bergus, G | 1 |
| Kishore, A; Snow, BJ | 1 |
| Falip, R; López-Arlandis, J; Manzanares, R; Martín, R; Matías-Guiu, J; Provencio, R; Ruiz, C | 1 |
| Kovacs, AB; Mally, J; Stone, TW | 1 |
| Dierks, T; Grosse, H; Kuhn, W; Müller, T; Rommelspacher, H | 1 |
| Dubois, B; Montastruc, JL | 1 |
| Bloem, BR; Klaassen, AA; van Hilten, JJ | 1 |
| Fazzini, E; Fowler, JS; Volkow, ND | 1 |
| Korczyn, AD; Nisipeanu, P | 1 |
| Hely, MA; Morris, JG | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Chan, P; DeLanney, LE; Di Monte, DA; Irwin, I; Jakowec, MW; Langston, JW; Royland, JE | 1 |
| Temlett, JA | 1 |
| Heinonen, EH; Mäki-Ikola, O; Myllylä, VV; Rinne, UK; Sotaniemi, K | 1 |
| Lengyel, J; Magyar, K; Szende, B; Tekes, K | 1 |
| Shan, DE; Yeh, SI | 1 |
| Lai, CT; Yu, PH | 1 |
| Fahn, S; Godbold, J; Langston, JW; Olanow, CW | 1 |
| Heinonen, E; Mäki-Ikola, O | 1 |
| Araya, F; Castillo, JL; Miranda, CM; Sáez, D | 1 |
| Ajax, T; Dobson, J; Rodnitzky, R | 1 |
| Myllylä, VV; Sotaniemi, K; Suominen, K; Tolonen, U; Turkka, J | 1 |
| Boas, J; Larsen, JP | 1 |
| Cui, L; LeWitt, P; Oakes, D | 1 |
| Arenas, J; Benito-León, J; Campos, Y; Gasalla, T; Jiménez-Jiménez, FJ; Martín, MA; Molina, JA; Ortí-Pareja, M; Rubio, JC | 1 |
| Armstrong, RA; Blair, JA; Hodgkins, PS; Winsper, SJ | 1 |
| Sethi, KD | 1 |
| Hakulinen, P; Heinonen, EH; Mäki-Ikola, O; Myllylä, VV; Sotaniemi, KA | 1 |
| Kondo, T; Mizuno, Y | 1 |
| Schulzer, M | 1 |
| Stern, MB | 1 |
| Ahtila, S; Kaakkola, S; Lyytinen, J; Teräväinen, H; Tuomainen, P | 1 |
| Jenner, P; Schapira, AH; Silva, MT | 1 |
| Jiménez-Jiménez, FJ; Molina, JA | 1 |
| Boonkongchuen, P; Churchyard, A; Lees, AJ; Mathias, CJ | 1 |
| Tolosa, E; Valldeoriola, F | 1 |
| McCallum, RW; Sarosiek, I; Shifflett, J; Soykan, I; Wooten, GF | 1 |
| Oakes, D | 1 |
| Oertel, WH; Quinn, NP | 1 |
| Baudewig, J; Bruns, D; Paulus, W; Tergau, F; Ziemann, U | 1 |
| Hagell, P; Odin, P; Vinge, E | 1 |
| Imke, S | 1 |
| Breteler, MM | 1 |
| Abrams, KR | 1 |
| Arenas, J; Benito-León, J; Cisneros, E; de Bustos, F; Gasalla, T; Jiménez-Jiménez, FJ; Molina, JA; Navarro, JA; Ortí-Pareja, M; Tallón-Barranco, A | 1 |
| Chouinard, S; Fahn, S | 1 |
| De Weerdt, W; Dom, R; Lesaffre, E; Nieuwboer, A | 1 |
| Ben-Shlomo, Y; Churchyard, A; Head, J; Hurwitz, B; Lees, AJ; Ockelford, J; Overstall, P | 1 |
| Bernardi, G; Bonci, A; Federici, M; Mercuri, NB; Scarponi, M; Siniscalchi, A | 1 |
| Brannan, T; Martínez-Tica, J; Prikhojan, A; Yahr, MD | 1 |
| Ruggieri, S; Silver, DE | 1 |
| Heinonen, EH; Myllylä, V | 1 |
| Coyle, J; Hobson, P; Meara, J | 1 |
| Heinonen, E; Myllylä, V | 1 |
| Hägglund, J; Heinonen, EH; Kaugesaar, T; Kontants, H; Mäki-Ikola, O; Pålhagen, S; Palm, R; Turunen, J | 1 |
| Aguilar, MV; de Bustos, F; González-Muñoz, MJ; Jiménez-Jiménez, FJ; Martínez-Para, MC; Martínez-Salio, A; Mateos-Vega, CJ; Meseguer, I; Molina, JA; Ortí-Pareja, M; Zurdo, M | 1 |
| Heinonen, EH; Kilkku, O; Lammintausta, R; Larsen, JP; Mäki-Ikola, O; Myllylä, VV; Olanow, CW; Pålhagen, S; Przuntek, H; Rinne, UK; Sotaniemi, KA | 1 |
| Koller, WC | 1 |
| Counsell, C | 1 |
| Mahmood, I | 1 |
| Althaus, JS; Fici, GJ; VonVoigtlander, PF | 1 |
| Aaltonen, H; Heinonen, E; Kilkku, O; Mäki-Ikola, O | 1 |
| Meco, G; Raschetti, R; Spila-Alegiani, S; Vanacore, N | 1 |
| Conrad, B; Dichgans, J; Kraus, PH; Krauseneck, P; Pergande, G; Przuntek, H; Rinne, U; Schimrigk, K; Schnitker, J; Vogel, HP | 1 |
| Hauser, RA; Zesiewicz, TA | 1 |
| Hubble, JP | 1 |
| Bryson, HM; Chrisp, P; Milne, RJ | 1 |
| Castronuovo, J; Feigin, A; Innis, RB; Marek, KL; Seibyl, JP; Sheff, K; Zoghbi, S | 1 |
| Durif, F | 1 |
| Barcenilla, B; Berbel, A; de Bustos, F; Fernández-Vivancos, E; Gómez-Escalonilla, C; Hernánz, A; Jiménez-Jiménez, FJ; Molina, JA; Villanueva, C; Zurdo, M | 1 |
| Stacy, M | 1 |
| Ghaemi, M; Rudolf, J; Schmülling, S | 1 |
| Alessandri, MG; Chen, K; Fornai, F; Gesi, M; Giorgi, FS; Shih, JC | 1 |
| Bräutigam, C; Dionisi-Vici, C; Hoffken, H; Hoffmann, GF; Leuzzi, V; Rizzo, C; Smeitink, JA; Steebergen-Spanjers, GC; Wevers, RA | 1 |
| Dirr, A; Gerlach, M; Gerstner, A; Götz, ME; Harth, R; Janetzky, B; Kuhn, W; Riederer, P | 1 |
| Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
| Myllylä, V | 1 |
| Brusa, L; Gasparini, M; Meco, G; Vanacore, N | 1 |
| Haapaniemi, TH; Kallio, MA; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Archer, T; Fredriksson, A; Palomo, T | 1 |
| Casas, M; Pérez, V; Prat, G; Rubi, A; Unzeta, M | 1 |
| Arenas, J; Barcenilla, B; Berbel, A; Camacho, A; De Bustos, F; Gómez, P; Gómez-Escalonilla, C; Jiménez-Jiménez, FJ; Molina, JA; Vargas, C; Zurdo, M | 1 |
| Häussler, M; Hoffmann, GF; Wevers, RA | 1 |
| Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA | 1 |
| Haapaniemi, TH; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U | 1 |
| Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM | 1 |
| Ball, J | 1 |
| Miyoshi, K | 1 |
| Ben-Shlomo, Y; Head, J; Katzenschlager, R; Lees, AJ | 1 |
| Horiuchi, E; Kanazawa, I; Murata, M | 1 |
| Jankovic, J | 1 |
| Ebadi, M; El Refaey, H; Sharma, S; Shavali, S | 1 |
| Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N | 1 |
| Djaldetti, R; Melamed, E; Ziv, I | 1 |
| Fahn, S; Kieburtz, K; Lang, A; Langston, JW; LeWitt, P; Oakes, D; Olanow, CW; Penney, JB; Rudolph, A; Shoulson, I; Tanner, C | 1 |
| Bhattacharya, KF; Kaufmann, H; Nouri, S; Olanow, CW; Yahr, MD | 1 |
| Vécsei, L | 1 |
| Foley, P; Gerlach, M; Riederer, P | 1 |
| Bonuccelli, U; Del Dotto, P | 1 |
| Rascol, O | 1 |
| Iida, Y; Saji, H; Shimazu, S; Takahata, K; Tamashiro, A; Yoneda, F | 1 |
| Hauser, RA; Hubble, JP; Truong, DD | 1 |
| Double, K; Gerlach, M; Reichmann, H; Riederer, P | 1 |
| Okamoto, K; Tanaka, M | 1 |
| de la Llave, Y; Garcia de Yébenes, J; Garcia-Borreguero, D; Larrosa, O; Schwarz, C | 1 |
| Kelsberg, G; Rich, J; Schreck, J; Ward, R | 1 |
| Boyce, M; Clarke, A; Corn, TH; Johnson, ES; Johnston, A; MacMahon, DG; Mallard, N; Warrington, S | 1 |
| Antkiewicz-Michaluk, L; Herman, ZS; Obuchowicz, E; Romańska, I | 1 |
| Czub, M; Czub, S; Gosztonyi, G; Koutsilieri, E; Müller, JG; Riederer, P; Sopper, S; Stahl-Hennig, C; Ter Meulen, V; Villinger, F | 1 |
| Bustamante, D; Bustamante, L; Goiny, M; Herrera-Marschitz, M; Segura-Aguilar, J | 1 |
| Clarke, CE | 1 |
| Castro, A; Dapena, MD; Linazasoro, G; Van Blercom, N | 1 |
| Nielsen, KK; Stimpel, H; Werdelin, LM; Winge, K | 1 |
| Kang, SY; Lee, MH; Lee, SK; Sohn, YH | 1 |
| Clarke, C; Moore, AP | 3 |
| Lang, AE; Marras, C; McDermott, MP; Naglie, G; Rochon, PA; Rudolph, A; Tanner, CM | 1 |
| Klein, C; Rabey, JM; Stryjer, R; Treves, TA | 1 |
| Mitsumoto, Y; Mori, A; Moriizumi, T; Nakai, M; Ohashi, S | 1 |
| Kurlan, R | 1 |
| Bryla, J; Chodnicka, K; Doroszewska, R; Drozak, J; Winiarska, K | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Waters, C | 1 |
| Akaike, A; Katsuki, H; Shimazu, S; Takahata, K; Yoneda, F | 1 |
| Inoue, H; Taguchi, Y; Takashima, S | 1 |
| Counsell, CE; Ives, N; Macleod, AD; Stowe, R | 1 |
| Bhat, V; Weiner, WJ | 1 |
| Burgut, FT; Henchcliffe, C; Schumacher, HC | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Hägglund, J; Heinonen, E; Kaugesaar, T; Mäki-Ikola, O; Pålhagen, S; Palm, R | 1 |
| Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I | 1 |
| Jain, S; Lo, SE | 1 |
| Das, SK; Gangopadhya, PK; Ray, J; Roy, T | 1 |
| Brodsky, MA; Koudelka, C; Swarztrauber, K | 1 |
| Adachi, K; Kondo, T; Kusumoto, H; Miwa, H; Shimazu, S | 1 |
| Herkes, GK; McKay, D; Meagher, LJ; Needham, M | 1 |
| Axelsson, J; Bengtsson, E; Bergström, M; Långström, B; Razifar, P; Schneider, H | 1 |
| Agnihotri, N; Mothersill, C; Poon, RC; Seymour, C | 1 |
| Bertoni, J; Kricorian, G; Leehey, M; Lew, MF; Pahwa, R | 1 |
| Annanmaki, T; Murros, K; Muuronen, A | 1 |
| Chen, JJ; Fernandez, HH | 2 |
| Klivényi, P; Vécsei, L | 1 |
| Concolino, D; Moricca, MT; Muzzi, G; Pascale, MG; Rapsomaniki, M; Strisciuglio, P | 1 |
| Ben-Shlomo, Y; Evans, A; Head, J; Katzenschlager, R; Lees, AJ; Schrag, A | 1 |
| Jost, WH; Klasser, M; Reichmann, H | 1 |
| Aasly, JO; Beiske, AG; Bekkelund, SI; Dietrichs, E; Larsen, JP; Tysnes, OB; Vilming, ST | 1 |
| Pirtosek, Z | 1 |
| Caslake, R; Counsell, C; Ives, N; Macleod, A; Stowe, R | 1 |
| Basaran, S; Karaca, E; Seven, M; Yosunkaya, E; Yüksel, A | 1 |
| Schneemilch, C | 1 |
| Chan, KY; Fung, CW; Hui, J; Ko, CH; Lam, CW; Low, L; Mak, CM; Siu, S; Wong, VC; Yau, E; Yeung, WL | 1 |
| Chi, CS; Lee, HF; Tsai, CR | 1 |
| Imamura, K; Nagatsu, T; Okayasu, N | 1 |
| Chen, R; Chuang, R; Hamani, C; Hodaie, M; Lim, SY; Lozano, AM; Mazzella, F; Moro, E; Neagu, B; Saha, U; Steeves, T; Tsang, EW | 1 |
| Munhoz, RP; Teive, HA; Zavala, JA | 1 |
| Sheehan, J; Thorpe, M; Wilson, L | 1 |
| Magyar, K; Szökő, E; Tábi, T; Vécsei, L | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Almeida, KJ; Campos Sousa, RN; de Oliveira Filho, MC; Guimarães Silva, JS; Lopes Nery, PC | 1 |
| Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Oertel, WH; Ries, V | 1 |
| Hayashi, R; Kohsaka, M; Oeda, T; Sawada, H; Sudoh, S; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K | 1 |
| Miklya, I | 1 |
| Alken, RG; Feltmann, K; Konradsson-Geuken, Å; Malmlöf, T; Schilström, B; Schneider, F; Svensson, TH | 1 |
| Ellmén, J; Kieburtz, K; Kuoppamäki, M; Vahteristo, M | 1 |
| Hasegawa, T | 1 |
| Doyu, M; Ibi, T; Niwa, J; Taguchi, S | 1 |
| Canning, SD; Wang, XP; Zhang, LL | 1 |
| Grünblatt, E; Müller, T; Riederer, P | 1 |
| Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Binde, CD; Gåsemyr, J; Klemp, M; Natvig, B; Tvete, IF | 1 |
| Alborghetti, M; Nicoletti, F | 1 |
| Asano, AGC; Asano, NMJ; de Souza, PRE; Dos Santos, EUD; Duarte, EBC; Maia, MMD; Miranda, LMR | 1 |
| Chen, XB; Jiang, DQ; Jiang, LL; Li, MX; Zhou, XW | 1 |
| Parambi, DGT | 1 |
| Binde, CD; Gåsemyr, JI; Klemp, M; Natvig, B; Tvete, IF | 1 |
| Agnieszka, W; Małgorzata, K; Paweł, P | 1 |
| Jost, WH | 1 |
| Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
113 review(s) available for levodopa and selegiline
| Article | Year |
|---|---|
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
An integrated approach to patient management in Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1992 |
Recent progress in the treatment of Parkinson's disease.
Topics: Amantadine; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1992 |
Early therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease; Selegiline | 1992 |
[Drug therapy of Parkinson disease].
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Selegiline | 1992 |
[Current therapeutic approach in Parkinson disease].
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Fetal Tissue Transplantation; Humans; Levodopa; Mesencephalon; Parkinson Disease; Selegiline; Vitamin E | 1992 |
["Widening horizons" in the clinical application of selegiline].
Topics: Alzheimer Disease; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1992 |
Treatment strategies for extension of levodopa effect.
Topics: Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Selegiline | 1992 |
[The dopamine agonist, lisuride, in the therapy of Parkinson disease].
Topics: Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline | 1992 |
A review of the pharmacology of selegiline.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Drug Interactions; Humans; Isoenzymes; Levodopa; Monoamine Oxidase; Neurotransmitter Agents; Parkinson Disease; Selegiline; Survival Rate | 1991 |
Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Adrenal Glands; Adult; Antiparkinson Agents; Brain Chemistry; Child; Child, Preschool; Cytoplasmic Granules; Dyskinesia, Drug-Induced; Environmental Pollutants; Fetus; Humans; Levodopa; Middle Aged; Palliative Care; Parkinson Disease; Prevalence; Research; Selegiline; Substantia Nigra; Time Factors | 1990 |
Nigral degeneration in Parkinson's disease in relation to clinical features.
Topics: Corpus Striatum; Humans; Levodopa; Nerve Degeneration; Neural Pathways; Neurologic Examination; Parkinson Disease; Selegiline; Substantia Nigra | 1991 |
Deprenyl: the exciting possibility of protective effect.
Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1991 |
Drug therapy for Parkinson's disease in the elderly.
Topics: Aged; Amantadine; Antiparkinson Agents; Carboxy-Lyases; Dopamine Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1990 |
The modern management of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Humans; Levodopa; Parkinson Disease; Selegiline | 1990 |
[Slowing the progression of Parkinson syndrome by early administration of deprenyl].
Topics: Animals; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline | 1990 |
[Protective therapy in Parkinson's disease].
Topics: Animals; Humans; Levodopa; Pargyline; Parkinson Disease; Selegiline | 1990 |
Selegiline in the treatment of Parkinson's disease.
Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
New perspectives in the treatment of Parkinson's disease.
Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Selegiline; Sincalide | 1986 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
Pharmacological approaches to Parkinson's disease in the different phases of evolution.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline | 1986 |
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Topics: Animals; Brain; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Serotonin; Tyramine | 1986 |
'On-off' phenomenon: description, incidence and management.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1987 |
R-(-)-deprenyl and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Phenethylamines; Pyridines; Selegiline; Stereoisomerism | 1987 |
Controversies in the management of Parkinson's disease.
Topics: Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1986 |
Update on the treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline; Time Factors | 1985 |
Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Biogenic Amines; Humans; Iproniazid; Levodopa; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Selegiline | 1980 |
Update on antiparkinsonian agents.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance | 1982 |
[Biochemical bases of Parkinson disease].
Topics: Acetylcholine; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Selegiline; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase | 1984 |
Anti-parkinsonian drugs today.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Dopamine beta-Hydroxylase; Droxidopa; Humans; Kinetics; Levodopa; Mental Disorders; Parasympatholytics; Parkinson Disease; Selegiline | 1984 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
[Stage-adjusted treatment of idiopathic Parkinson syndrome].
Topics: Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Cholinergic Antagonists; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline | 1995 |
Parkinson's disease: managing symptoms and preserving function.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Delayed-Action Preparations; Drug Combinations; Fetal Tissue Transplantation; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
[Changing drug therapy of Parkinson disease].
Topics: Antiparkinson Agents; Corpus Striatum; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline; Synaptic Transmission | 1993 |
Treatment options in Parkinson's disease.
Topics: Cholinergic Antagonists; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Selegiline | 1995 |
Drug treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Cholinergic Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
[Parkinson's disease--current topics].
Topics: Adult; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1994 |
Update on the management of Parkinson's disease.
Topics: Depression; Diagnosis, Differential; Dopamine Agents; Hallucinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1993 |
Strategies in the treatment of early Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Neurologic Examination; Parkinson Disease; Selegiline | 1993 |
Treatment of Parkinson's disease. From theory to practice.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Dopamine; Drug Combinations; Free Radicals; Humans; Levodopa; Oxygen; Parkinson Disease; Selegiline | 1994 |
The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
Topics: Aging; Alzheimer Disease; Animals; Avoidance Learning; Catalase; Corpus Striatum; Drug Therapy, Combination; Learning; Levodopa; Male; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra; Superoxide Dismutase | 1993 |
Die Pathoklise [Parkinson's disease].
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra | 1993 |
MAO-B inhibitors in Parkinson's disease.
Topics: Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Receptors, Dopamine; Selegiline | 1993 |
Treatment of Parkinson's disease.
Topics: Alzheimer Disease; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Neurons; Parkinson Disease; Receptors, Dopamine; Selegiline | 1993 |
Moderate Parkinson's disease. Strategies for maximizing treatment.
Topics: Antiparkinson Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Controversies in the therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Treatment options for early Parkinson's disease.
Topics: Algorithms; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Treatment of early Parkinson's disease: are complicated strategies justified?
Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Selegiline | 1996 |
Drug management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Selegiline; Trihexyphenidyl | 1996 |
Controversies in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 1996 |
New directions in the drug treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Bromocriptine; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
(-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Role of selegiline in combination therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
Topics: Age Factors; Animals; Apoptosis; Dopamine; Humans; Hypertension; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neurotoxins; Norepinephrine; Parkinson Disease; PC12 Cells; Rats; Selegiline | 1996 |
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Topics: 1-Methyl-4-phenylpyridinium; Antioxidants; Apoptosis; Clinical Trials as Topic; Dopamine; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline | 1996 |
Selegiline and mortality in Parkinson's disease.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline | 1996 |
Parkinson's disease: diagnosis, pathology, and treatment.
Topics: Antiparkinson Agents; Diagnosis, Differential; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Selegiline; Syndrome | 1997 |
Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1997 |
[Neuroprotective and neurorestorative therapy in Parkinson's disease].
Topics: Antiparkinson Agents; Apoptosis; Brain Tissue Transplantation; Chelation Therapy; Corpus Striatum; Dopamine; Erythrocytes; Free Radicals; Gangliosides; Genetic Therapy; Glutathione Peroxidase; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Oxidative Stress; Parkinson Disease; Selegiline; Selenium; Vitamin E | 1997 |
Early idiopathic parkinsonism: initiation and optimization of treatment.
Topics: Amantadine; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1994 |
Mid-stage parkinsonism with mild motor fluctuations.
Topics: Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Dopamine Agonists; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1994 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1997 |
Pregnancy in Parkinson's disease: a review of the literature and a case report.
Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Levodopa; Mice; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Rabbits; Rats; Selegiline | 1998 |
Initiating therapy for Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1998 |
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1998 |
Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
Topics: Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline; Survival Rate | 1998 |
Neuroprotection for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Vitamin E | 1998 |
Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Selegiline | 1998 |
Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline; Survival Analysis; Treatment Outcome | 1998 |
Management of early Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Treatment Outcome | 1999 |
Novel drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Biological Availability; Dopamine Agonists; Free Radical Scavengers; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1999 |
Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.
Topics: Cost of Illness; Humans; Levodopa; Parkinson Disease; Quality of Life; Selegiline; Treatment Outcome | 1992 |
Treating and preventing levodopa-induced dyskinesias: current and future strategies.
Topics: Clinical Trials as Topic; Dopamine Agonists; Forecasting; Levodopa; Movement Disorders; Polypharmacy; Receptors, Dopamine D2; Selegiline | 1999 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Tyrosine hydroxylase deficiency with severe clinical course: clinical and biochemical investigations and optimization of therapy.
Topics: Child, Preschool; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Male; Metabolism, Inborn Errors; Monoamine Oxidase Inhibitors; Selegiline; Tyrosine 3-Monooxygenase | 2000 |
[Drug therapy of Parkinson's disease].
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline | 1997 |
[Parkinson's disease].
Topics: Antiparkinson Agents; Depression; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline | 2001 |
Parkinson's disease therapy: treatment of early and late disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors | 2001 |
Neuroprotective actions of selegiline.
Topics: Animals; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Selegiline; Treatment Outcome | 2002 |
[Serotonin syndrome: report of a fatal case and review of the literature].
Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism; Fatal Outcome; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome | 2002 |
Recent advances in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 2002 |
The relevance of preclinical studies for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Drug Evaluation, Preclinical; Humans; Levodopa; Neuroprotective Agents; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 2003 |
Clinical pharmacokinetics of cabergoline.
Topics: Age Factors; Antiparkinson Agents; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Ergolines; Female; Food-Drug Interactions; Humans; Kidney Diseases; Levodopa; Liver Diseases; Male; Selegiline; Sex Factors | 2003 |
Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptors, Dopamine; Selegiline | 2003 |
Clinical inquiries. What is the best initial treatment of Parkinson's disease?
Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 2003 |
A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
Topics: Antiparkinson Agents; Brain; Cost-Benefit Analysis; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Selegiline; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2004 |
Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 2003 |
Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Selegiline; Thalamus | 2004 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Other pharmacological treatments for motor complications and dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Periodicity; Purinergic P1 Receptor Antagonists; Purines; Selegiline | 2005 |
Monoamine oxidase B inhibitors for early Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Selegiline | 2005 |
Parkinson's disease.
Topics: Deep Brain Stimulation; Deglutition Disorders; Dopamine Agonists; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Selegiline; Thalamus | 2005 |
Parkinson's disease. Diagnosis and the initiation of therapy.
Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor | 2005 |
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Diet Therapy; Dopamine Agents; Drug Evaluation; Drug Interactions; Expert Testimony; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2005 |
Patient page. Slowing down a "slow" movement disorder: selegiline's benefit in treating Parkinson disease.
Topics: Disease Progression; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 2006 |
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Topics: Aged; Aging; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Homes for the Aged; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Selegiline | 2007 |
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2007 |
[Motor symptoms in Parkinson disease].
Topics: Age Factors; Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Dystonia; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Selegiline; Treatment Outcome; Tremor | 2008 |
'Bad guys' among the antiparkinsonian drugs.
Topics: Antiparkinson Agents; Benzophenones; Cholinergic Antagonists; Cognition; Dopamine Agonists; Humans; Levodopa; Nitrophenols; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Survival Rate; Tolcapone; Treatment Outcome | 2009 |
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Topics: Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline | 2009 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
Pooled analysis of phase III with entacapone in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Clinical Trials, Phase III as Topic; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline | 2014 |
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome | 2016 |
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes | 2017 |
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2018 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2019 |
Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis.
Topics: Activities of Daily Living; Combined Modality Therapy; Drug Therapy, Combination; Humans; Levodopa; Mental Status and Dementia Tests; Parkinson Disease; Selegiline; Treatment Outcome | 2020 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation | 2020 |
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Topics: Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2020 |
How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.
Topics: Antiparkinson Agents; Dietary Supplements; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2022 |
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agents; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2022 |
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
89 trial(s) available for levodopa and selegiline
| Article | Year |
|---|---|
Experiences with L-deprenyl in Parkinsonism.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1978 |
A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group.
Topics: Dopamine Agents; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Research Design; Selegiline; Severity of Illness Index | 1992 |
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.
Topics: Affect; Aged; Catalase; Free Radicals; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Superoxide Dismutase | 1992 |
Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT).
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; France; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1991 |
L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Selegiline; Time Factors | 1991 |
Deprenyl and the progression of Parkinson's disease.
Topics: Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline | 1990 |
L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
Topics: Aged; Carbidopa; Follow-Up Studies; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline | 1990 |
The effect of dietary protein on the efficacy of L-dopa: a double-blind study.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Selegiline | 1989 |
Big first scored with nerve diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Designer Drugs; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline; Substantia Nigra | 1989 |
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Random Allocation; Selegiline | 1989 |
Pergolide and selegiline for Parkinson's disease.
Topics: Animals; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Pergolide; Phenethylamines; Selegiline | 1989 |
Effect of deprenyl on the progression of disability in early Parkinson's disease.
Topics: Activities of Daily Living; Clinical Trials as Topic; Drug Therapy, Combination; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline; Vitamin E | 1989 |
Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.
Topics: Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Prospective Studies; Selegiline | 1989 |
Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Prospective Studies; Selegiline | 1989 |
A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease--an interim analysis.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline | 1989 |
Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Randomized Controlled Trials as Topic; Selegiline | 1989 |
Multicenter trial of L-Deprenyl in Parkinson disease.
Topics: Adult; Affect; Aged; Clinical Trials as Topic; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Tremor | 1986 |
Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Placebos; Random Allocation; Selegiline | 1987 |
Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Self Concept | 1987 |
Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism.
Topics: Aged; Clinical Trials as Topic; Depression; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Thioxanthenes | 1987 |
R-(-)-deprenyl in the treatment of end-of-dose akinesia.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Models, Theoretical; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline | 1987 |
The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
Topics: Benserazide; Clinical Trials as Topic; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
Deprenyl versus placebo in Parkinson disease: a double-blind study.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline | 1988 |
Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
Topics: Aged; Animals; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Placebos; Selegiline | 1988 |
Clinical trial for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Levodopa; Models, Neurological; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Pyridines; Pyridinium Compounds; Selegiline | 1985 |
Deprenyl in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Dopamine; Double-Blind Method; Drug Combinations; Epinephrine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1981 |
[Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
Topics: Aged; Carboxy-Lyases; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1983 |
Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
Topics: Aged; Biotransformation; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1980 |
The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Bromocriptine; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Levodopa; Male; Parkinson Disease; Prospective Studies; Selegiline; Statistics, Nonparametric; Treatment Outcome | 1995 |
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group.
Topics: Adult; Age Factors; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Risk Factors; Selegiline; Sex Factors; Vitamin E | 1995 |
Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease.
Topics: Aged; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Random Allocation; Selegiline; Treatment Outcome | 1995 |
Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Treatment Outcome | 1995 |
Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism.
Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Carbidopa; Citrate (si)-Synthase; Electron Transport; Electron Transport Complex II; Electron Transport Complex III; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Multienzyme Complexes; NAD(P)H Dehydrogenase (Quinone); Oxidoreductases; Parkinson Disease; Plateletpheresis; Selegiline; Succinate Dehydrogenase | 1995 |
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
Topics: Aged; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1994 |
[A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1994 |
Visual control of arm movement in Parkinson's disease.
Topics: Adult; Aged; Attention; Benserazide; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline | 1994 |
Die Pathoklise [Parkinson's disease].
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra | 1993 |
Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
Topics: Activities of Daily Living; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; France; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome | 1993 |
Selegiline in de novo parkinsonian patients: the Finnish study.
Topics: Activities of Daily Living; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Finland; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1993 |
Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Selegiline; Treatment Outcome | 1993 |
Effects of selegiline dosing on motor fluctuations in Parkinson's disease.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Selegiline | 1993 |
The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers.
Topics: Adult; Antiparkinson Agents; Drug Interactions; Humans; Infusions, Intravenous; Levodopa; Male; Placebos; Reference Values; Selegiline | 1995 |
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Cause of Death; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Selegiline; Time Factors; Treatment Failure | 1995 |
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E | 1996 |
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E | 1996 |
Single vs multiple daily dosing of aminoglycosides.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline; Treatment Outcome | 1996 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
[A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1996 |
An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
Topics: Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Movement; Parkinson Disease; Selegiline; Single-Blind Method | 1996 |
Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.
Topics: Analysis of Variance; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies; Reflex; Selegiline; Tilt-Table Test | 1997 |
The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Denmark; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Norway; Parkinson Disease; Selegiline | 1997 |
The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
Topics: Activities of Daily Living; Adult; Aged; Antioxidants; Antiparkinson Agents; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome; Vitamin E | 1997 |
Cerebrospinal fluid carnitine levels in patients with Parkinson's disease.
Topics: Acylation; Aged; Antiparkinson Agents; Carnitine; Female; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Reference Standards; Selegiline | 1997 |
Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
Topics: Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Prospective Studies; Regression Analysis; Selegiline; Time Factors | 1997 |
Mortality associated with selegiline in Parkinson's disease. What do the available data mean?
Topics: Antiparkinson Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Patient Selection; Prospective Studies; Research Design; Selegiline; United Kingdom | 1997 |
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Nitriles; Parkinson Disease; Selegiline | 1997 |
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1997 |
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Severity of Illness Index | 1997 |
Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs.
Topics: Administration, Oral; Adult; Analysis of Variance; Bromocriptine; Dopamine Agonists; Dopamine Antagonists; Electromyography; Evoked Potentials, Motor; Female; Haloperidol; Humans; Levodopa; Magnetics; Male; Motor Cortex; Physical Stimulation; Reference Values; Selegiline; Sulpiride | 1997 |
Experience with tranylcypromine in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Erectile Dysfunction; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders; Time Factors; Tranylcypromine; Tyramine | 1998 |
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry
Topics: Antiparkinson Agents; Bromocriptine; Cause of Death; Disabled Persons; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Proportional Hazards Models; Selegiline; Survival Rate; Treatment Failure | 1998 |
Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Disabled Persons; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Probability; Selegiline; Time Factors | 1998 |
SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa.
Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors | 1999 |
Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
Topics: Aged; Antiparkinson Agents; Biological Transport; Carbidopa; Cocaine; Corpus Striatum; Dopamine; Drug Therapy, Combination; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Monoamine Oxidase; Occipital Lobe; Parkinson Disease; Selegiline; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease.
Topics: Aged; Blood Pressure; Bromocriptine; Cardiovascular System; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 2000 |
Suppressed sympathetic skin response in Parkinson disease.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Electric Stimulation; Evoked Potentials; Evoked Potentials, Auditory; Female; Foot; Hand; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Reference Values; Selegiline; Skin; Sympathetic Nervous System | 2000 |
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Incidence; Levodopa; Male; Parkinson Disease; Selegiline; Treatment Outcome | 2001 |
Zonisamide has beneficial effects on Parkinson's disease patients.
Topics: Aged; Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Isoxazoles; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Rats; Selegiline; Treatment Outcome; Zonisamide | 2001 |
The effect of deprenyl washout in patients with long-standing Parkinson's disease.
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Double-Blind Method; Drug Administration Schedule; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Psychiatric Status Rating Scales; Selegiline; Time Factors; Treatment Outcome | 2002 |
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Topics: Aged; Antioxidants; Antiparkinson Agents; Chi-Square Distribution; Confidence Intervals; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Tocopherols; Treatment Outcome | 2002 |
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Blood Pressure; Carbidopa; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Supine Position | 2003 |
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Topics: Adenosine A2 Receptor Antagonists; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chronic Disease; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nausea; Parkinson Disease; Purines; Safety; Selegiline; Treatment Outcome | 2003 |
L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment.
Topics: Aged; Antiparkinson Agents; Disorders of Excessive Somnolence; Double-Blind Method; Female; Humans; Levodopa; Parkinson Disease; Pergolide; Polysomnography; Reaction Time; Selegiline | 2003 |
A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
Topics: Administration, Oral; Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Satisfaction; Reference Values; Selegiline; Treatment Outcome; Tyramine | 2003 |
Effects of dopaminergic treatment on bladder function in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Disease Progression; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sex Characteristics; Surveys and Questionnaires; Urinary Bladder Diseases; Urination Disorders; Urodynamics; Urologic Diseases | 2004 |
The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease; Pulse; Rest; Selegiline; Supine Position | 2005 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
Selegiline slows the progression of the symptoms of Parkinson disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Time Factors | 2006 |
Quality of life in Parkinson's disease--Indian scenario.
Topics: Aged; Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; Female; Humans; India; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Sickness Impact Profile; Surveys and Questionnaires; Treatment Outcome | 2006 |
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Polypharmacy; Selegiline; Tablets; Time Factors; Treatment Outcome | 2007 |
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Topics: Antiparkinson Agents; Bromocriptine; Disability Evaluation; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Quality of Life; Selegiline | 2008 |
216 other study(ies) available for levodopa and selegiline
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Topics: Bromocriptine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1979 |
The possible mechanisms of action of (-)deprenyl in Parkinson's disease.
Topics: Acetylcholine; Animals; Biogenic Amines; Biological Transport; Cats; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Muscle Contraction; Muscle, Smooth; Parkinson Disease; Phenethylamines; Rabbits; Rats; Selegiline | 1978 |
Overview of present day treatment of Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Receptors, Dopamine; Selegiline | 1978 |
Long term treatment with L-deprenyl.
Topics: Benserazide; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1978 |
Recent observations on the clinical pharmacology of (-)deprenyl.
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Heart Rate; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Time Factors; Tyramine | 1978 |
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline; Vanilmandelic Acid | 1978 |
Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
Topics: Bromocriptine; Clinical Trials as Topic; Dopamine Agents; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline | 1992 |
Therapy of Parkinson's disease: are we at the end of the road?
Topics: Antiparkinson Agents; Dopamine Agents; Humans; India; Levodopa; Neurologic Examination; Parkinson Disease; Selegiline; Vitamin E | 1992 |
Combination therapy of parkinsonism with deprenyl.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; India; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pilot Projects; Selegiline | 1992 |
Pergolide can induce soluble superoxide dismutase in rat striata.
Topics: Animals; Brain Chemistry; Corpus Striatum; Cytosol; Dopamine; Enzyme Induction; Isatin; Levodopa; Male; Mitochondria; Pergolide; Rats; Rats, Wistar; Selegiline; Subcellular Fractions; Superoxide Dismutase | 1992 |
Neurotoxicity of levodopa on catecholamine-rich neurons.
Topics: Catecholamines; Cell Line; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Humans; Levodopa; Neuroblastoma; Neurons; Selegiline | 1992 |
Some new aspects of the effect of (-)deprenyl in Parkinson's disease--a retrospective study.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selegiline; Severity of Illness Index | 1992 |
Long-term experience with selegiline and levodopa in Parkinson's disease.
Topics: Aged; Humans; Levodopa; Longitudinal Studies; Middle Aged; Parkinson Disease; Selegiline | 1992 |
Emerging perspectives in Parkinson's disease.
Topics: Animals; Humans; Levodopa; MPTP Poisoning; Neurology; Parkinson Disease; Parkinson Disease, Secondary; Selegiline | 1992 |
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Topics: Age Factors; Blood Glucose; Blood Platelets; Carbidopa; Drug Therapy, Combination; Energy Metabolism; Female; Humans; Lactates; Lactic Acid; Levodopa; Lisuride; Male; Middle Aged; Mitochondria; Oxygen Consumption; Parkinson Disease; Receptors, Dopamine; Selegiline | 1992 |
Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Topics: Amphetamine; Animals; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catecholamines; Catechols; Clorgyline; Convulsants; Desipramine; Drug Interactions; Lethal Dose 50; Levodopa; Male; Mice; Motor Activity; Nitriles; Nomifensine; Pentanones; Selegiline; Synaptic Transmission; Yohimbine | 1991 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
Topics: Carboxy-Lyases; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Selegiline | 1990 |
Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl.
Topics: Humans; Levodopa; Lisuride; Nervous System; Parkinson Disease; Selegiline; Survival Analysis | 1991 |
Parkinson's disease: an epidemiologic method for distinguishing between symptomatic and neuroprotective treatments.
Topics: Aged; Epidemiologic Methods; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; United States | 1991 |
Experience with selegiline and levodopa in advanced Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1991 |
Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.
Topics: Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1991 |
Treating the progressive stages of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline | 1991 |
Selegiline (Eldepryl) for Parkinson's disease.
Topics: Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1991 |
[The effect of chronic treatment of deprenyl in animal models of Parkinson's disease].
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Rotation; Selegiline | 1991 |
Early therapy for Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Selegiline | 1991 |
The effect of long-term treatment with deprenyl on basal and L-dopa evoked dopamine release in vitro from the corpus striatum of aged rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Amphetamine; Animals; Corpus Striatum; Dopamine; In Vitro Techniques; Levodopa; Male; Rats; Selegiline | 1991 |
(-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity.
Topics: Aged; Benserazide; Catechol O-Methyltransferase; Erythrocytes; Female; Humans; Kinetics; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline | 1991 |
New concepts in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Diet; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Selegiline | 1990 |
L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Psychomotor Performance; Selegiline | 1990 |
Early combination with deprenyl: a retrospective analysis.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Retrospective Studies; Selegiline | 1990 |
Monoamine oxidase and oxidative stress at dopaminergic synapses.
Topics: Animals; Clorgyline; Corpus Striatum; Dopamine; Glutathione; Glutathione Reductase; Haloperidol; In Vitro Techniques; Levodopa; Male; Mice; Monoamine Oxidase; Oxidation-Reduction; Rats; Rats, Inbred Strains; Reserpine; Selegiline; Stress, Physiological; Substantia Nigra; Synapses; Synaptosomes | 1990 |
New drugs for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Quality of Life; Selegiline | 1990 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Facial dystonia: clinical features, prognosis and pharmacology in 31 patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Botulinum Toxins; Drug Combinations; Female; Haloperidol; Humans; Levodopa; Male; Meige Syndrome; Middle Aged; Phenethylamines; Prognosis; Selegiline | 1989 |
Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
New approaches in the use of selegiline for the treatment of Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Selegiline in the treatment of Parkinson's disease--long term experience.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
Topics: Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Hypersexuality with antiparkinsonian therapy.
Topics: Adult; Age Factors; Aged; Amantadine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Sex Factors; Sexual Behavior | 1989 |
Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase.
Topics: Animals; Behavior, Animal; Catalepsy; Catechol O-Methyltransferase Inhibitors; Central Nervous System; Haloperidol; Levodopa; Male; Motor Activity; Phenethylamines; Propiophenones; Rats; Selegiline; Specific Pathogen-Free Organisms | 1987 |
Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects.
Topics: Allylamine; Amines; Animals; Blood Pressure; Brain; Decerebrate State; Dose-Response Relationship, Drug; Drug Synergism; Heart Rate; Hydroxydopamines; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Rats; Rats, Inbred Strains; Selegiline | 1986 |
MPTP: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Basal Ganglia; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Pyridines; Selegiline | 1986 |
Investigation of dopamine content, synthesis, and release in the rabbit retina in vitro: I. Effects of dopamine precursors, reserpine, amphetamine, and L-DOPA decarboxylase and monoamine oxidase inhibitors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Dopamine; Female; Levodopa; Male; Monoamine Oxidase Inhibitors; Pargyline; Rabbits; Reserpine; Retina; Selegiline; Tyrosine | 1986 |
[Deprenyl as a co-adjuvant in the treatment of Parkinson disease].
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Topics: Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Retrospective Studies; Selegiline; Time Factors | 1986 |
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
Topics: Adult; Aged; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
(-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
Topics: Adult; Aged; Carboxy-Lyases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Body Temperature; Catalepsy; Clorgyline; Drug Interactions; Female; Haloperidol; Imipramine; Levodopa; Male; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Motor Activity; Nomifensine; Oxotremorine; Pargyline; Piperidines; Pyridazines; Rats; Rats, Inbred Strains; Reserpine; Selegiline; Stereotyped Behavior | 1987 |
Critical role of MAO inhibition in Parkinson's disease.
Topics: Acetylcholine; Animals; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Structure-Activity Relationship | 1987 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine | 1987 |
Current and future approaches to therapy.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline | 1987 |
Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain.
Topics: Animals; Brain; Catecholamines; Clorgyline; Corpus Striatum; Dopamine; Hypothalamus; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Norepinephrine; Pargyline; Rats; Rats, Inbred Strains; Selegiline | 1987 |
Parkinson's disease in the elderly: current management strategies.
Topics: Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1987 |
Milestones in the development of modern Parkinson therapy.
Topics: 2,3-Diketogulonic Acid; Alloxan; Behavior; Bromocriptine; Drug Combinations; Drug Therapy, Combination; Ferric Compounds; Humans; Levodopa; Neurology; Parkinson Disease; Selegiline; Tryptophan | 1987 |
R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Disability Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Phenethylamines; Selegiline | 1987 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1988 |
Deprenyl in Parkinson disease: personal experience.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Practical therapeutics: advances in the management of Parkinson's disease.
Topics: Ergolines; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
Topics: Adult; Aged; Benserazide; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Life Expectancy; Longitudinal Studies; Male; Middle Aged; Models, Biological; Phenethylamines; Retrospective Studies; Selegiline | 1985 |
Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
Topics: Apomorphine; Bromocriptine; Growth Hormone; Homovanillic Acid; Humans; Levodopa; Male; Metoclopramide; Monitoring, Physiologic; Neurosecretory Systems; Prolactin; Receptors, Dopamine; Schizophrenia; Selegiline; Time Factors | 1985 |
Deprenyl in Parkinson's disease.
Topics: Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline | 1982 |
The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
Topics: Animals; Brain; Catalase; Catecholamines; Dopamine; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Hydroxides; Hydroxyl Radical; Levodopa; Monoamine Oxidase; Nerve Degeneration; Neurons; Parkinson Disease; Rats; Selegiline; Superoxide Dismutase; Superoxides | 1983 |
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Benserazide; Dopamine; Humans; Levodopa; Monoamine Oxidase; Phenethylamines; Phenylacetates; Selegiline | 1983 |
Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
Topics: Animals; Brain Chemistry; Dextroamphetamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline; Stereotyped Behavior | 1984 |
Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease.
Topics: Benzamides; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegiline; Tiapamil Hydrochloride | 1984 |
Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients.
Topics: Aged; Disability Evaluation; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Middle Aged; Motor Skills; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
L-deprenyl in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1984 |
Deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Outcome and Process Assessment, Health Care; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Aged; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1983 |
Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Deprenyl (selegiline) in combination treatment of Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment.
Topics: Aged; Arousal; Behavior; Cognition; Drug Therapy, Combination; Emotions; Female; Humans; Levodopa; Male; Memory; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Time Factors | 1983 |
Human growth hormone and dopaminergic drugs, with special reference to deprenyl (selegiline): a summary of studies on volunteers.
Topics: Apomorphine; Bromocriptine; Dopamine; gamma-Aminobutyric Acid; Growth Hormone; Humans; Levodopa; Phenethylamines; Receptors, Dopamine; Selegiline; Synapses | 1983 |
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline).
Topics: Drug Therapy, Combination; Humans; Levodopa; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Time Factors | 1983 |
Observations made with L-deprenil (Jumex) in the long-term treatment of outpatients with Parkinson's syndrome.
Topics: Aged; Ambulatory Care; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Statistics as Topic; Time Factors | 1983 |
Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.
Topics: Aged; Brain Chemistry; Dopamine; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Parkinson Disease; Phenethylamines; Selegiline; Serotonin | 1980 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
Effects of L-deprenyl on human growth hormone secretion.
Topics: Adult; Apomorphine; Growth Hormone; Humans; Kinetics; Levodopa; Male; Phenethylamines; Selegiline; Tryptophan | 1981 |
Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats.
Topics: Animals; Clorgyline; Dopamine; Humans; Hydroxydopamines; Isomerism; Levodopa; Male; Oxidopamine; Phenethylamines; Rats; Rats, Inbred Strains; Selegiline; Stereotyped Behavior; Substantia Nigra | 1981 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Combinations; Female; Humans; Levodopa; Male; Methamphetamine; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Tyramine | 1982 |
The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
Topics: Amphetamine; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrogen-Ion Concentration; Levodopa; Methamphetamine; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1982 |
(-)Deprenyl in the treatment of Parkinson's disease.
Topics: 5-Hydroxytryptophan; Brain; Dopamine; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Serotonin | 1982 |
Clinicopharmacological study of long-term Jumex + Dopaflex combination treatment in Parkinson's syndrome.
Topics: Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Time Factors | 1982 |
[Initiation of treatment in Parkinson disease].
Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline | 1995 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Pergolide; Prognosis; Selegiline | 1995 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 1995 |
Antiparkinsonian therapies and brain mitochondrial complex I activity.
Topics: Animals; Antioxidants; Antiparkinson Agents; Antipsychotic Agents; Ascorbic Acid; Brain; Cholinergic Antagonists; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Mitochondria; NAD(P)H Dehydrogenase (Quinone); Rats; Rats, Sprague-Dawley; Selegiline | 1995 |
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Blood Platelets; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline; Serotonin; Treatment Outcome | 1995 |
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activity; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Selegiline | 1994 |
Parkinson's disease.
Topics: Apomorphine; Brain; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
Role of selegiline as initial monotherapy in early Parkinson's disease.
Topics: Activities of Daily Living; Drug Tolerance; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Safety; Selegiline; Time Factors; Tremor | 1994 |
Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
Topics: Animals; Behavior, Animal; Fetal Tissue Transplantation; Levodopa; Male; Mesencephalon; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotation; Selegiline; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase | 1994 |
Parkinson's disease: reorganization of the reach to grasp movement in response to perturbation of the distal motor patterning.
Topics: Aged; Antiparkinson Agents; Attention; Carbidopa; Drug Combinations; Female; Hand Strength; Humans; Kinesthesis; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline; Size Perception | 1994 |
[Bromocriptine-induced pleuropneumopathy].
Topics: Benserazide; Biperiden; Bromocriptine; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion; Pulmonary Atelectasis; Pulmonary Fibrosis; Radiography; Selegiline; Time Factors | 1994 |
L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Dopamine; Homovanillic Acid; Hydroxyl Radical; Levodopa; Microdialysis; Mitochondria; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Selegiline; Stereotaxic Techniques; Substantia Nigra | 1994 |
Drugs for Parkinson's disease.
Topics: Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1993 |
Neuropsychological correlates of L-deprenyl therapy in idiopathic parkinsonism.
Topics: Aged; Attention; Female; Frontal Lobe; Humans; Language; Learning; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Parkinson Disease; Selegiline; Space Perception; Verbal Learning | 1994 |
Deprenyl and the issue of neuroprotection.
Topics: Antioxidants; Cell Survival; Clinical Trials as Topic; Disability Evaluation; Drug Administration Schedule; Humans; Levodopa; Neurons; Parkinson Disease; Selegiline; Substantia Nigra; Vitamin E | 1994 |
L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Levodopa; Male; Monoamine Oxidase Inhibitors; Nerve Endings; Oxidopamine; Picolinic Acids; Rats; Rats, Sprague-Dawley; Selegiline | 1994 |
Disturbance of colour perception in Parkinson's disease.
Topics: Adult; Aged; Color Perception; Color Perception Tests; Computers; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1993 |
Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line.
Topics: Ascorbic Acid; Brain; Brain Neoplasms; Catecholamines; Cell Line; Drug Interactions; Female; Humans; Levodopa; Male; Neuroblastoma; Parkinson Disease; Quinones; Selegiline | 1993 |
New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
Topics: Brain; Central Nervous System Diseases; Dopamine; Female; Gene Expression; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1993 |
End-of-dose dystonia in Parkinson's disease.
Topics: Adult; Carbidopa; Dystonia; Humans; Infusions, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome | 1993 |
Protective effect of selegiline in the early and late phases of Parkinson's disease.
Topics: Age Factors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1993 |
Slowing of information processing in Parkinson's disease.
Topics: Aged; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Lisuride; Male; Mental Processes; Middle Aged; Neuropsychological Tests; Parkinson Disease; Problem Solving; Reaction Time; Selegiline; Thinking | 1993 |
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E | 1995 |
Selegiline in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline; Treatment Failure; United Kingdom | 1995 |
A 61-year-old man with Parkinson's disease.
Topics: 1-Naphthylamine; Antiparkinson Agents; Carbidopa; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Family Practice; Humans; Levodopa; Male; Middle Aged; Neurology; Neuroprotective Agents; Parkinson Disease; Selegiline; Sertraline; Vitamin E | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality.
Topics: Antiparkinson Agents; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Meta-Analysis as Topic; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
Topics: Antiparkinson Agents; Double-Blind Method; Levodopa; Parkinson Disease; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.
Topics: Antiparkinson Agents; Cause of Death; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline is effective and safe in early stages.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.
Topics: Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Research Design; Selegiline | 1996 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
Topics: Antiparkinson Agents; Cardiovascular Diseases; Cause of Death; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; Cysteinyldopa; Humans; Levodopa; Malondialdehyde; Methoxyhydroxyphenylglycol; Middle Aged; Oxidative Stress; Parkinson Disease; Selegiline | 1996 |
[Daily defined doses of parkinsonian drugs in Alcoi].
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Utilization; Humans; Levodopa; Parkinson Disease; Selegiline; Spain | 1996 |
Delayed development of symptomatic improvement by (--)-deprenyl in Parkinson's disease.
Topics: Aged; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Time Factors | 1995 |
Plasma levels of the beta-carbolines harman and norharman in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbolines; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Parkinson Disease; Selegiline | 1995 |
[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Risk Factors; Selegiline | 1996 |
Deprenyl's neuroprotective action remains unresolved.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Deprenyl and levodopa and Parkinson's disease progression.
Topics: Antiparkinson Agents; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Selegiline | 1996 |
Deprenyl in Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
Topics: Animals; Clorgyline; Corpus Striatum; Dopamine; Dopamine Agents; Female; Isoenzymes; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Saimiri; Selegiline; Substantia Nigra | 1996 |
Pallidotomy in Parkinson's disease.
Topics: Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; Globus Pallidus; Humans; Levodopa; Motor Skills; Neurons; Parkinson Disease; Patient Selection; Selegiline | 1996 |
R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells.
Topics: Antioxidants; Dopamine; Drug Synergism; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroblastoma; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Pargyline; Propylamines; Reactive Oxygen Species; Selegiline; Tumor Cells, Cultured | 1997 |
Study design problems of DATATOP study analysis.
Topics: Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Placebos; Randomized Controlled Trials as Topic; Selegiline; Vitamin E | 1996 |
[Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
Topics: Adult; Aged; Apomorphine; Electric Stimulation; Evoked Potentials, Somatosensory; Female; Frontal Lobe; Humans; Levodopa; Male; Median Nerve; Middle Aged; Motor Skills; Parietal Lobe; Parkinson Disease; Reaction Time; Selegiline; Walking | 1996 |
Current therapy of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Humans; Levodopa; Parkinson Disease; Patient Selection; Selegiline | 1997 |
Gallium-transferrin binding in treated and untreated Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Drug Therapy, Combination; Gallium; Humans; Levodopa; Middle Aged; Parkinson Disease; Protein Binding; Selegiline; Transferrin | 1997 |
Treatment of Parkinson's disease: disagreements.
Topics: Disease Progression; Humans; Levodopa; Parkinson Disease; Selegiline | 1997 |
Unexpected findings of study of selegiline have not been treated with caution its authors advised.
Topics: Antiparkinson Agents; Carboxy-Lyases; Humans; Levodopa; Parkinson Disease; Selegiline | 1997 |
Selegiline and excess mortality.
Topics: Antiparkinson Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1997 |
Parkinson's disease.
Topics: Antiparkinson Agents; Cholinergic Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1998 |
Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline | 1998 |
Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early.
Topics: Antiparkinson Agents; Bromocriptine; Decision Making; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline | 1998 |
Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease.
Topics: Aged; Cyclic GMP; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 1998 |
A frequency and correlation analysis of motor deficits in Parkinson patients.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Prognosis; Psychomotor Disorders; Psychomotor Performance; Selegiline; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 1998 |
Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Electrophysiology; Injections, Intraperitoneal; Levodopa; Male; Membrane Potentials; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Wistar; Selegiline | 1998 |
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; Levodopa; Male; Microdialysis; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline | 1995 |
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular System; Drug Therapy, Combination; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Valsalva Maneuver | 1998 |
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular System; Drug Therapy, Combination; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Valsalva Maneuver | 1998 |
Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Blood Proteins; Copper; Dopamine Agonists; Female; Humans; Iron; Levodopa; Male; Manganese; Metals, Heavy; Middle Aged; Nutritional Status; Parkinson Disease; Reference Values; Selegiline; Spectrophotometry, Atomic; Trace Elements; Vitamin A; Zinc | 1998 |
Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease?
Topics: Blood Platelets; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1998 |
Pharmacological approaches to counter the toxicity of Dopa.
Topics: Animals; Benzothiazoles; Cells, Cultured; Cerebellum; Cytoplasmic Granules; Glutathione; Levodopa; Neuroprotective Agents; Pramipexole; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Selegiline; Thiazoles; Vitamin E | 1998 |
Mortality cancer risk in parkinsonian patients: a population-based study.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Neoplasms; Parkinson Disease; Poisson Distribution; Retrospective Studies; Rome; Selegiline | 1999 |
Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Selegiline; Thiamine; Thiamine Monophosphate; Thiamine Pyrophosphate | 1999 |
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone | 1999 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Olanzapine; Paranoid Disorders; Parkinson Disease; Piperidines; Pirenzepine; Selegiline; Severity of Illness Index | 1999 |
Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study.
Topics: Animals; Brain Chemistry; Corpus Striatum; Dopamine; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Monoamine Oxidase; Phenethylamines; Rats; Selegiline; Species Specificity | 1999 |
Altered redox state of platelet coenzyme Q10 in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antioxidants; Antiparkinson Agents; Biomarkers; Blood Platelets; Coenzymes; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Oxidation-Reduction; Parkinson Disease; Selegiline; Ubiquinone | 2000 |
A possible association between exposure to n-hexane and parkinsonism.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Electromyography; Evoked Potentials, Auditory, Brain Stem; Evoked Potentials, Somatosensory; Hexanes; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Occupational Diseases; Parkinsonian Disorders; Selegiline; Solvents | 2000 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
Effects of MAO inhibitors upon MPTP mice chronically treated with suprathreshold doses of L-dopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Clorgyline; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Phenelzine; Phenethylamines; Selegiline; Thiazoles; Tryptamines | 2000 |
The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
Topics: Adrenergic Agents; Animals; Clorgyline; Corpus Striatum; Dopamine Agents; Dopamine Uptake Inhibitors; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 2000 |
Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Case-Control Studies; Dopamine Agonists; Female; Humans; Insulin; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline | 2000 |
L-dopa and selegiline for tyrosine hydroxylase deficiency.
Topics: Antiparkinson Agents; Child; Female; Humans; Levodopa; Selegiline; Tyrosine 3-Monooxygenase | 2001 |
Freezing of gait in patients with advanced Parkinson's disease.
Topics: Adult; Age of Onset; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Female; Freezing; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Regression Analysis; Retrospective Studies; Selegiline | 2001 |
Advances in managing Parkinson's disease.
Topics: Activities of Daily Living; Algorithms; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 2001 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Electromyography; Female; Genes, Recessive; Immunohistochemistry; Indoles; Levodopa; Male; Memory Disorders; Mice; Mice, Inbred C3H; Mice, Neurologic Mutants; Motor Activity; Neurons; Parkinson Disease, Secondary; Postural Balance; Selegiline; Tyrosine 3-Monooxygenase | 2001 |
Current advances in Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Benzothiazoles; Brain Stem; Catechols; Depression; Dopamine Agonists; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles | 2001 |
Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; France; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Treatment Outcome | 2002 |
Monoamine oxidase inhibitors--is it time to up the TEMPO?
Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome | 2003 |
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; Drug Synergism; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Reaction Time; Recovery of Function; Selegiline; Serotonin | 2003 |
[Therapy for patients with early-stage Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Selegiline; Trihexyphenidyl | 2003 |
Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-Antagonists; Animals; Chromatography, High Pressure Liquid; Clonidine; Corpus Striatum; Dopamine; Homovanillic Acid; Immunohistochemistry; Levodopa; Male; Mice; MPTP Poisoning; Neuropeptide Y; Neuroprotective Agents; Selegiline; Serotonin | 2003 |
Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs.
Topics: Animals; Cell Count; Central Nervous System Viral Diseases; Dopamine Agents; Dose-Response Relationship, Drug; Gene Expression; Immunohistochemistry; In Situ Hybridization; Inflammation; Interleukin-1; Interleukin-6; Levodopa; Macaca mulatta; Monoamine Oxidase; Selegiline; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Staining and Labeling; Statistics, Nonparametric; Time Factors; Tumor Necrosis Factor-alpha; Virus Replication | 2004 |
Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats.
Topics: Animals; Biogenic Monoamines; Corpus Striatum; Dicumarol; Enzyme Inhibitors; Levodopa; Male; NAD(P)H Dehydrogenase (Quinone); Rats; Rats, Sprague-Dawley; Selegiline | 2004 |
Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease.
Topics: Analgesics, Non-Narcotic; Anti-Infective Agents; Antiparkinson Agents; Combined Modality Therapy; Consciousness Disorders; Dantrolene; Deep Brain Stimulation; Diagnosis, Differential; Diagnostic Errors; Dystonic Disorders; Encephalitis; Female; Fluid Therapy; Foot; Humans; Levodopa; Malignant Hyperthermia; Middle Aged; Muscle Relaxants, Central; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome; Tachycardia | 2004 |
Levodopa-responsive parkinsonism in hereditary spastic paraplegia with thin corpus callosum.
Topics: Adolescent; Antiparkinson Agents; Benztropine; Cognition Disorders; Corpus Callosum; Electroencephalography; Female; Gait Disorders, Neurologic; Humans; Levodopa; Magnetic Resonance Imaging; Male; Muscle Weakness; Neuropsychological Tests; Parkinson Disease; Selegiline; Spastic Paraplegia, Hereditary; Tremor | 2004 |
Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
Topics: Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Likelihood Functions; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Parkinson Disease; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Selegiline; Survival Analysis; Time; Tocopherols | 2005 |
Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; Brain Chemistry; Bromocriptine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Hindlimb Suspension; Immobility Response, Tonic; Immunohistochemistry; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Nerve Tissue Proteins; Selegiline; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome | 2005 |
Contribution of L-3,4-dihydroxyphenylalanine metabolism to the inhibition of gluconeogenesis in rabbit kidney-cortex tubules.
Topics: Alanine; Animals; Aspartic Acid; Caprylates; Depression, Chemical; Dihydroxyacetone; Dopamine; Gluconeogenesis; Glutathione; Glutathione Disulfide; Glycerol; Hydrogen Peroxide; In Vitro Techniques; Kidney Tubules; Levodopa; Male; Phosphoenolpyruvate Carboxykinase (GTP); Pyruvic Acid; Rabbits; Selegiline; Tyramine | 2005 |
Effects of selegiline on antioxidant systems in the nigrostriatum in rat.
Topics: Animals; Antioxidants; Antiparkinson Agents; Catalase; Cerebral Cortex; Corpus Striatum; Enzyme Activation; Glutathione; Hippocampus; Levodopa; Male; Organ Culture Techniques; Oxidative Stress; Rats; Rats, Wistar; Selegiline; Substantia Nigra; Superoxide Dismutase | 2006 |
[A case of interval form of carbon monoxide poisoning with a remarkable recovery].
Topics: Acute Disease; Aged; Antiparkinson Agents; Brain; Carbon Monoxide Poisoning; Cytidine Diphosphate Choline; Drug Therapy, Combination; Female; Humans; Hyperbaric Oxygenation; Levodopa; Parkinson Disease, Secondary; Selegiline | 2005 |
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Topics: Algorithms; Antiparkinson Agents; Bayes Theorem; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Models, Biological; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2006 |
Initial pharmacotherapy in a population of veterans with Parkinson disease.
Topics: Age Factors; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Databases, Factual; Dementia; Dopamine Agonists; Drug Prescriptions; Drug Utilization; Geriatrics; Humans; Levodopa; Male; Medicine; Middle Aged; Neurology; Northwestern United States; Parkinson Disease; Practice Patterns, Physicians'; Primary Health Care; Psychiatry; Psychology; Retrospective Studies; Selegiline; Specialization; United States; United States Department of Veterans Affairs; Veterans | 2006 |
Effects of subchronic treatment with selegiline on L-DOPA-induced increase in extracellular dopamine level in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Space; Homovanillic Acid; Injections, Intraperitoneal; Levodopa; Male; Microdialysis; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rats; Rats, Sprague-Dawley; Selegiline; Time Factors | 2006 |
Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy.
Topics: Acetaminophen; Acyclovir; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiparkinson Agents; Antiviral Agents; Anxiety; Carbidopa; Ceftriaxone; Cervical Vertebrae; Depression; Dexamethasone; Diazepam; Doxepin; Electroconvulsive Therapy; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Oxycodone; Pain; Parkinson Disease; Selegiline; Spinal Injuries | 2006 |
A new application of pre-normalized principal component analysis for improvement of image quality and clinical diagnosis in human brain PET studies--clinical brain studies using [11C]-GR205171, [11C]-L-deuterium-deprenyl, [11C]-5-Hydroxy-L-Tryptophan, [11
Topics: Antiemetics; Brain; Brain Mapping; Carbon Radioisotopes; Deuterium; Humans; Image Processing, Computer-Assisted; Levodopa; Piperidines; Positron-Emission Tomography; Selegiline; Tetrazoles | 2006 |
Bystander effects of ionizing radiation can be modulated by signaling amines.
Topics: Animals; Apoptosis; Bystander Effect; Calcium; Cell Line; Gamma Rays; Glycine; Humans; Levodopa; Mice; Mice, Inbred C57BL; Nicotine; Oncorhynchus mykiss; Receptors, Serotonin, 5-HT3; Selegiline; Serotonin; Signal Transduction; Skin; Urinary Bladder | 2007 |
Low plasma uric acid level in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Body Mass Index; Energy Intake; Female; Ferritins; Humans; Levodopa; Male; Mass Screening; Middle Aged; Parkinson Disease; Plasma; Risk Factors; Selegiline; Spouses; Uric Acid | 2007 |
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2008 |
Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients.
Topics: 5-Hydroxytryptophan; Aromatic Amino Acid Decarboxylase Inhibitors; Biomarkers; Carbidopa; Child, Preschool; Dietary Proteins; Dihydropteridine Reductase; Dopa Decarboxylase; Dopamine Agents; Drug Monitoring; Drug Therapy, Combination; Enzyme Inhibitors; Genetic Predisposition to Disease; Humans; Infant; Infant, Newborn; Italy; Levodopa; Monoamine Oxidase Inhibitors; Mutation; Neonatal Screening; Neurologic Examination; Phenotype; Phenylketonurias; Prolactin; Selegiline; Time Factors; Treatment Outcome | 2008 |
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Quality of Life; Selegiline; Treatment Outcome | 2008 |
Marked improvement in Segawa syndrome after L-dopa and selegiline treatment.
Topics: Child, Preschool; Diseases in Twins; Drug Therapy, Combination; Dystonic Disorders; Humans; Infant; Levodopa; Male; Pedigree; Selegiline; Syndrome; Treatment Outcome; Tyrosine 3-Monooxygenase | 2010 |
[General anaesthesia for neurological diseases].
Topics: Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Intravenous; Autonomic Nervous System; Brain; Bromocriptine; Dopamine Agonists; Humans; Intubation; Levodopa; Monoamine Oxidase Inhibitors; Muscle Relaxants, Central; Nervous System Diseases; Neurodegenerative Diseases; Neurosurgery; Parkinson Disease; Piperidines; Premedication; Preoperative Care; Propofol; Remifentanil; Selegiline; Stereotaxic Techniques; Syndrome | 2010 |
Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.
Topics: Adolescent; Adult; Child; Child, Preschool; Deficiency Diseases; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinsonian Disorders; Phenotype; Prolactin; Selegiline; Severity of Illness Index; Treatment Outcome; Tyrosine 3-Monooxygenase | 2011 |
Tyrosine hydroxylase deficiency in Taiwanese infants.
Topics: Child; Child, Preschool; Codon, Nonsense; Dystonic Disorders; Female; Humans; Infant; Levodopa; Male; Mutation, Missense; Neurologic Examination; Selegiline; Tyrosine 3-Monooxygenase | 2012 |
Cerebral blood flow and freezing of gait in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Circulation; Disability Evaluation; Drug Therapy, Combination; Female; Gait Disorders, Neurologic; Humans; Iofetamine; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Radiopharmaceuticals; Selegiline; Tomography, Emission-Computed, Single-Photon | 2012 |
Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Precision Medicine; Selegiline; Subthalamic Nucleus; Treatment Outcome | 2012 |
Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
Topics: Ankle; Antiparkinson Agents; Benserazide; Benzothiazoles; Drug Therapy, Combination; Edema; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Parkinson Disease; Pramipexole; Selegiline | 2012 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline | 2013 |
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.
Topics: Administration, Oral; Amphetamine; Biological Availability; Drug Evaluation; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Tablets | 2013 |
Zoophilia and Parkinson's disease.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sexual Dysfunctions, Psychological | 2013 |
Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Survival; Dopamine Agents; Dopaminergic Neurons; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neural Stem Cells; Neurogenesis; Neuroprotective Agents; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Selegiline | 2014 |
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
Topics: Amantadine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Delusions; Dopamine Agents; Hallucinations; Humans; Illusions; Levodopa; Logistic Models; Multivariate Analysis; Parkinson Disease; Psychotic Disorders; Risk Factors; Selegiline; Surveys and Questionnaires | 2014 |
Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
Topics: Animals; Indans; Learning Disabilities; Levodopa; Male; Neurons; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tetrabenazine | 2014 |
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Deuterium; Disease Models, Animal; Dopamine; Forelimb; Levodopa; Male; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase | 2015 |
[Neurological common diseases in the super-elder society. Topics: IV. Parkinson's disease; 2. Current and new drugs for initial treatment of Parkinson's disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 2014 |
[Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
Topics: Aged; Benzothiazoles; Delayed-Action Preparations; Drug Substitution; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pramipexole; Selegiline | 2015 |
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors; Treatment Outcome | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
Topics: Antiparkinson Agents; Catechols; Cross-Sectional Studies; Dopamine; Dopamine Agonists; Genotype; Humans; Indans; Levodopa; Motor Activity; Nitriles; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D1; Receptors, Dopamine D3; Selegiline | 2019 |